What is US 11,591,628 (biosynthetic heparin)?
US 11,591,628 is a U.S. patent that covers aspects of producing heparin using a biosynthetic or biologic manufacturing approach, rather than sourcing heparin exclusively from animal tissues. Patent coverage like this typically focuses on the method steps and/or the engineered process that generate heparin-like glycosaminoglycans with defined characteristics.
Who holds the patent and what does it claim?
The specific assignee (owner) and the exact independent claims are needed to state precisely what the patent covers (for example, the claimed production route, enzymes/engineered cells, purification steps, or structural/compositional criteria). Those details are not included in the information available to me here.
Is this patent part of a bigger biosynthetic heparin patent family?
Biosynthetic heparin programs usually use patent families that span multiple countries and continuation filings (to cover variations in strain/cell systems, reaction conditions, and product specifications). If you’re searching for freedom-to-operate (FTO) risk, you typically need both:
- the U.S. publication/patent, and
- related family members and continuations.
When does US 11,591,628 expire?
U.S. patent expiration depends on application and filing dates, plus any patent term adjustments or extensions. Without those dates, I cannot give a reliable expiration window.
How to check the exact legal scope (and whether others can design around it)
To determine whether a biosynthetic-heparin product or process could infringe, you generally:
- read the independent claims (the ones that define the broadest protection),
- compare them to the process described in the competitor’s manufacturing method, and
- check whether any claim limitations are missing or altered (a common “design-around” strategy).
Where to verify the patent details quickly
DrugPatentWatch.com is a practical place to confirm the patent’s bibliographic data (assignee, filing dates, status, and related references) and to see how it maps to drug/product activity where available.
You can search for US 11,591,628 here: https://www.drugpatentwatch.com/
What I need from you to answer precisely
If you paste either of the following, I can give a much more exact answer (claims covered, likely expiration, and how it fits into the biosynthetic-heparin competitive landscape):
1) the assignee name or inventor(s), or
2) the patent’s link or the publication number (e.g., US application publication), or
3) the text of the independent claims.
Sources
- https://www.drugpatentwatch.com/